Name: Ser140 Myelin Proteolipid Protein (139-151) Depalmitoylated
Availability: InStock
Rating: 4.5 (89 reviews)

[Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated), human, bovine, dog, mouse, rat CAS NO.122018-58-0

[Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated), human, bovine, dog, mouse, rat is a synthetic peptide analog corresponding to residues 139-151 of the myelin proteolipid protein (PLP) with a serine substitution at position 140 (replacing the natural cysteine) and provided in a de-palmitoylated form. This research-grade reagent represents a modified immunodominant epitope of PLP, a key component of central nervous system myelin. The product is available as a lyophilized powder with high purity and is intended for preclinical research applications in neuroimmunology, autoimmune demyelinating disease models, and comparative immunology studies across multiple species. It serves as a valuable tool for investigating T-cell responses, immune tolerance mechanisms, and the pathogenesis of demyelinating disorders such as multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) in various animal models.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	[Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated), human, bovine, dog, mouse, rat
CAS NO.	122018-58-0
Appearance	White to off-white lyophilized powder
Molecular Formula	C72H104N20O17
Molecular Weight	1521.7g/mol
Purity (RP-HPLC)	≥ 95.0%
Solubility	Soluble in water, dilute acetic acid (e.g., 0.1%), or phosphate-buffered saline (PBS). For best results, first dissolve in a small volume of 0.1% acetic acid or sterile water to prepare a 1-5 mg/mL stock solution, then dilute further with the desired assay buffer.
Endotoxin	< 1.0 EU/mg
Biological Activity	This peptide corresponds to an immunodominant epitope of myelin proteolipid protein (PLP), specifically modified with a Serine substitution at position 140 and provided in a de-palmitoylated form. It is widely used in research on autoimmune demyelinating diseases, such as experimental autoimmune encephalomyelitis (EAE), to study T-cell responses and immune tolerance mechanisms.
Storage Conditions	Lyophilized powder: Store at -20°C or below in a desiccated environment, protected from light, for long-term stability. Reconstituted solution: Aliquot and store at ≤ -20°C. Avoid repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

The mechanism of action involves this peptide serving as an antigenic epitope that can be presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells to T-cells. The serine substitution at position 140 (replacing the natural palmitoylated cysteine) and de-palmitoylation modify the peptide's structure and potentially its immunogenicity compared to the native PLP sequence. When administered to susceptible animal models, this peptide can induce T-cell activation and proliferation, leading to an autoimmune response against myelin components. This T-cell-mediated immune response can result in inflammation, demyelination, and neurological symptoms characteristic of experimental autoimmune encephalomyelitis (EAE), making this peptide a tool for studying the immunopathogenesis of demyelinating diseases.

2.PRODUCT INDICATIONS

This PLP peptide analog is indicated for research use only in preclinical studies investigating autoimmune demyelinating diseases, neuroimmunology, and T-cell-mediated autoimmunity. It serves as an immunogenic peptide for inducing experimental autoimmune encephalomyelitis (EAE) in various animal models (mouse, rat, etc.) to study the pathogenesis of multiple sclerosis-like diseases. The product is used in T-cell proliferation assays, cytokine profiling studies, and investigations of immune tolerance mechanisms. The availability of species-specific variants (human, bovine, dog, mouse, rat) makes it particularly valuable for comparative immunology studies, cross-species reactivity assessments, and translational research. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

3.CLINICAL EFFICACY OF PRODUCT

As a research reagent, [Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated) does not have established clinical efficacy for therapeutic use in human patients. This peptide analog is used exclusively as an experimental tool to induce autoimmune disease in animal models for research purposes. It has not undergone clinical development or received regulatory approval for any medical indication. While studies using this peptide have contributed to the understanding of autoimmune demyelinating diseases and potential therapeutic targets, the product itself has no proven clinical efficacy or safety profile for human use. It is intended solely for laboratory research applications in appropriate scientific settings and should not be used in clinical contexts.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.